Search

Search Constraints

You searched for: Author/Creator Parren, Paul

Search Results

1. C1q potentiates DR5 agonist activity by a mixture of two DR5-specific HexaBody® molecules. (October 2018)

2. Hexamerization-enhanced CD37 and CD20 antibodies synergize in CDC to kill patient-derived CLL cells with unprecedented potency. (October 2018)

3. Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. (4th November 2015)

4. Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Issue 2 (December 2015)

5. Templated insertions at VD and DJ junctions create unique B‐cell receptors in the healthy B‐cell repertoire. Issue 12 (27th August 2020)